Transarterial chemoembolization with or without sorafenib for intermediate-stage hepatocellular carcinoma

Bookmark and Share
Published: 31 May 2015
Views: 2227
Prof Guohong Han - Xijing Hospital, Fourth Military Medical University, Xi'an, China

Dr Han talks to ecancertv at ASCO 2015 about a multicentre retrospective study to evaluate the efficacy of combination therapy over transarterial chemoembolisation (TACE) alone.

The study compared the overall survival between patients with ≥ grade 2 sorafenib-related dermatologic adverse events in the combination therapy group and patients treated with TACE alone.